Literature DB >> 12540333

Improved detection of depression in primary care through severity evaluation.

Donald E Nease1, Michael S Klinkman, Robert J Volk.   

Abstract

OBJECTIVES: To determine whether the use of a symptom severity measure to augment an existing Diagnostic and Statistical Manual of Mental Disorders-Third Edition, Revised (DSM-III-R) criteria-based depression screener (PRIME-MD) would decrease the difficulties associated with depression screening in primary care by filtering out patients with minimal impairment. STUDY
DESIGN: The study design was secondary data analysis. POPULATION: The study sample comprised 1317 patients, with intentional oversampling by ethnicity and sex, presenting for routine care at a university family practice center in Galveston, Texas. OUTCOMES MEASURED: The primary outcomes were cross-sectional, health-related quality-of-life outcomes of subjects who met symptom severity criteria as well as criteria for a DSM-III-R mood disorder. Health care utilization outcomes were examined as secondary outcomes.
RESULTS: The combination of a 6-item depression severity instrument and the PRIME-MD resulted in 71% of depressed subjects being categorized as severely symptomatic and 29% as minimally symptomatic. Severely symptomatic subjects had significantly worse SF-36 Mental Health Component Summary scale (MCS) scores than did minimally symptomatic subjects (32.8 vs 43.5, P <.05). Minimally symptomatic subjects had MCS scores similar to those of a third group of subjects who did not meet DSM-III-R "threshold" criteria for mood disorder but who were severely symptomatic. Adjusted health care utilization was higher for the initial 3-month charge period in the severely symptomatic depressed subjects compared with minimally symptomatic depressed subjects ($679.20 vs $462.38, P <.05).
CONCLUSIONS: The 6-item depression severity measure effectively separated patients meeting DSM-III-R "threshold" depression criteria into 2 groups: one presenting with severe symptoms and impairment and the other presenting with mild symptoms and significantly less impairment. A strategy of initial screening using a brief depression severity instrument, followed with a DSM criteria-based instrument, could decrease the immediate clinician workload by one third and focus treatment on those most likely to benefit.

Entities:  

Mesh:

Year:  2002        PMID: 12540333

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  5 in total

1.  DSM depression and anxiety criteria and severity of symptoms in primary care: cross sectional study.

Authors:  Donald E Nease; James E Aikens
Journal:  BMJ       Date:  2003-11-01

2.  Detection of major depression in Ugandan primary health care settings using simple questions from a subjective well-being (SWB) subscale.

Authors:  Wilson Winstons Muhwezi; Hans Agren; Seggane Musisi
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2006-11-02       Impact factor: 4.328

3.  A 4-year follow-up study of syndromal and sub-syndromal anxiety and depression symptoms in the general population: the HUNT study.

Authors:  Ottar Bjerkeset; Hans M Nordahl; Sara Larsson; Alv A Dahl; Olav Linaker
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-12-06       Impact factor: 4.328

4.  The Four-Dimensional Symptom Questionnaire (4DSQ): a validation study of a multidimensional self-report questionnaire to assess distress, depression, anxiety and somatization.

Authors:  Berend Terluin; Harm W J van Marwijk; Herman J Adèr; Henrica C W de Vet; Brenda W J H Penninx; Marleen L M Hermens; Christine A van Boeijen; Anton J L M van Balkom; Jac J L van der Klink; Wim A B Stalman
Journal:  BMC Psychiatry       Date:  2006-08-22       Impact factor: 3.630

5.  Screening and diagnosing depression in women visiting GPs' drop in clinic in Primary Health Care.

Authors:  Ranja Stromberg; Estera Wernering; Anna Aberg-Wistedt; Anna-Karin Furhoff; Sven-Erik Johansson; Lars G Backlund
Journal:  BMC Fam Pract       Date:  2008-06-13       Impact factor: 2.497

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.